Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Illumina

MacroGenics

These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.

Three Cancer Treatment Stocks to Buy Right Now

The genetic testing industry is still in its infancy, but this leader is comfortably profitable and growing at a healthy clip.

The 1 Stock I'd Buy Right Now: Genomic Health

AngioDynamics

Ensign Group

Ionis Pharma

Masimo

National Research Corp

Osiris Therapeutics

These healthcare stocks will help you not only profit from the growing demand, but also the growing tech in the healthcare sector.

7 A-Rated Healthcare Stocks for Industry Expansion

A good start to the year and no increased guidance mean slower growth ahead.

Genomic Health's Strong Growth Spooks Investors

After Genomic's stellar first quarter, investors are getting jittery about growth in the second half.

Here's Why Shares of Genomic Health Dropped Today

Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.

Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up

Genomic Health, Inc. (GHDX) CEO Kim Popovits on Q1 2019 Results - Earnings Call Transcript

Genomic Health (GHDX) delivered earnings and revenue surprises of 17.24% and 1.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Genomic Health (GHDX) Q1 Earnings and Revenues Top Estimates

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Gilead Sciences

Myriad Genetics

Novartis

Invitae

Spark Therapeutics

Pacific Biosciences of California

REGENXBIO

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

After spending years pouring capital into scaling its technology platform, Genomic Health finally turned profitable in 2018.

A profitable, fast-growing genetic testing platform

Genomic Health continues to see positive developments for Oncotype DX Breast Recurrence Score tests.

Genomic Health's New Positive Data to Boost Test Uptake

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.

Here's Why You Should Invest in Genomic Health (GHDX) Now

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Genomic Health Stock (GHDX)